Whitehawk Therapeutics
WHWK
33 hedge funds and large institutions have $26.2M invested in Whitehawk Therapeutics in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
124% more capital invested
Capital invested by funds: $11.7M → $26.2M (+$14.5M)
57% more funds holding
Funds holding: 21 → 33 (+12)
1.23% more ownership
Funds ownership: 1.54% → 2.76% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.53M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.88M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.66M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$583K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$464K |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$322K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$46K |
| 4 |
Goldman Sachs
New York
|
-$37K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$31K |
WHWK Hedge Fund Activity: Q3 2020 in Review
33 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q3 2020, worth a combined $26.2M — up 124% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new WHWK positions and 5 closed out — a net gain of 12 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $5.53M. The largest seller was Renaissance Technologies, cutting an estimated $464K.
- 33 institutional investors held Whitehawk Therapeutics (WHWK) as of Q3 2020, up from 21 in Q2 2020.
- Funds reported $26.2M of Whitehawk Therapeutics stock for Q3 2020, up 124% quarter-over-quarter.
- 17 funds opened new Whitehawk Therapeutics positions in Q3 2020 and 5 closed out, a net change of +12 holders.
- The largest Whitehawk Therapeutics buyer in Q3 2020 was Ikarian Capital, an estimated $5.53M added.
- The largest Whitehawk Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $464K sold.
Based on aggregated 13F filings for Q3 2020.